Could a drug combo stop smoldering myeloma in its tracks?

NCT ID NCT04776395

Recruiting now Disease control Sponsor: Emory University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests iberdomide, an immunotherapy drug, alone or with dexamethasone in 68 people with intermediate- or high-risk smoldering multiple myeloma. The goal is to see if the treatment can shrink or control the cancer cells and delay progression to active myeloma. Participants will be monitored with blood tests, urine tests, and bone marrow biopsies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: iberdomide and dexamethasone
What this could lead to: If successful, this could offer a new treatment option to delay or prevent smoldering myeloma from becoming active cancer.
What could go wrong: This is an early-phase trial with only 68 participants, so results may not apply broadly. Side effects from the drugs could also limit tolerability.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SMOLDERING PLASMA CELL MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Smoldering Multiple Myeloma smoldering plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SMOLDERING PLASMA CELL MYELOMA

Contacts and locations

Locations

Emory University Hospital/Winship Cancer Institute
RECRUITING

Atlanta, Georgia, 30322, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.